Consensus of Analysts' Estimates > pré-Q2 2022





Poll date	Participants	Median TP
12/07/22	14	120.00
BUY	HOLD	SELL
79%	14%	7%

The consensus is the medianof analyst estimates which are compiled and calculated by Vara Research. It is based on the projections made by analysts covering Solvay. Any opinions, estimates or forecasts regarding Solvay's performance made by these analysts and therefore also the consensus figures are theirs alone and do not represent opinions or forecasts of Solvay or its Management. By making this consensus information of its results available on a quarterly basis, Solvay does not mean or otherwise input to endrose such information.

otherwise imply to endorse such information.							Fill in	Fill in	Fill in	Fill in	Fill in	Fill in	Fill in
			20	021 actua	ls		2022 actuals			Estim	ates		
		Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	FY 2023	FY 2024
N	et sales (1)	2,373	2,456	2,573	2,703	10,105	3,055	3,099	2,930	2,895	11,916	12,106	12,517
	ATERIALS	689	711	752	751	2,903	879	858	838	795	3,404	3,581	3,758
CH	HEMICALS	791	820	856	891	3,357	1,039	1,050	986	971	4,038	3,992	4,036
SC	DLUTIONS	891	925	964	1,058	3,838	1,135	1,156	1,077	1,102	4,482	4,566	4,690
Corporate and Business Services, sales		3	1	1	2	7	2	1	1	2	6	6	6
	EBITDA (1)	583	602	599	572	2,356	712	683	622	544	2,550	2,611	2,695
M. (2)	ATERIALS	206	220	246	207	879	259	254	237	212	956	1,016	1,079
Ž CH	HEMICALS	240	249	234	286	1,009	279	265	237	228	992	973	1,029
CH SC Corporate and Business Service	DLUTIONS	173	171	177	180	701	238	229	208	185	857	852	
Corporate and Business Service	s, EBITDA	-36	-38	-58	-101	-233	-64	-63	-64	-67	-251	-257	-260
Depreciation & amortization (excluding	ng PPA ⁽³⁾)	-201	-179	-177	-199	-756	-186	-189	-190	-200	-769	-791	-807
EBIT (excluding non-recurring elements & M&	A effects)	382	424	421	374	1,600	526	489	428	344	1,779	1,847	1,865
Net financial charges (including coupons of perpetual hyb	rid bonds)	-63	-54	-64	-54	-235	-49	-50	-50	-50	-202	-192	-190
Inc	ome taxes	-70	-83	-74	-59	-287	-96	-106	-94	-87	-378	-405	-424
Profit from discontinued	operations	1	0	1	1	2	1	0	0	0	0	0	(
Profit attributable to non-controlling	g interests	-9	-10	-10	-11	-41	-12	-11	-11	-10	-43	-43	-44
Profit attributable to Solvay sha	reholders	240	276	273	250	1,040	369	313	271	213	1,160	1,183	
ρο Δ΄ Profit attributable to Solvay sharehold	BIT, IFRS	169	333	300	271	1,073	457	441	380	246	1,565	1,605	1,714
Profit attributable to Solvay sharehole	ders, IFRS	104	222	255	143	724	337	302	256	150	1,038	1,066	
Gross	DPS (€) (4)	-	-	-	-	3.85	-	-	-	-	3.95	4.05	4.15
Capex (continuing o	perations)	-100	-141	-171	-324	-736	-151				-880	-903	-929
Free cash flow to Solvay shareholders (continuing o	perations)	282	135	276	150	843	216				692	873	947
Free cash flow to Solvay shareholde Underlying net debt (including perpetual hybrodes)	rs (total) (5)	282	123	276	149	830	232				703	873	947
Underlying net debt (including perpetual hyb		4,157	4,221	4,052	3,949	3,949	3,912				3,766	3,284	2,979
-	ROCE (7)	-	-	-	-	11.4%	-	-	-	-			
FCF con	version (8)	-	-	-	-	37.6%	-	-	-	-			

Items contributed by less than 5 analysts not taken into account

million.

more car

- (1) Segmentation since H2 2021: Materials: Specialty Polymers, Composite Materials; Chemicals: Soda Ash, Peroxides and Silica, and its Coatis and Rusvinyl; Solutions: Novecare, Technology Solutions, Aroma, Special Chem and Oil&Gas
- (2) For full disclosure and definition of Underlying alternative metrics on a proforma basis, please refer to appropriate press releases issued by Solvay on Feb 25 and March 17, 2016.
- (3) Purchase Price Allocation.
- (4) Dividend Per Share pending for approval at the General Shareholder meeting generally in May of the current year
- (5) Cash flow from continuing operations (including dividends from associates and joint ventures) + cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments) and excluding loans to associates and non-consolidated companies).
- (6) Unaudited 2018 pro forma financial information concerning the adoption of IFRS 16 "Leases". The Group adopted IFRS 16, using a modified retrospective approach, as of January 1, 2019, i.e. without restating prior reporting periods presented. The pro forma information presents the impact on the Group's financial reporting as if the adoption of IFRS 16 had taken place on January 1, 2018. This pro forma financial information only pertains to leases that were classified as operating leases in accordance with IAS 17.
- (7) ROCE: Return on Capital employed, calculated as the ratio between underlying EBIT (before adjustment for the amortization of PPA) and capital employed. Capital employed consists of net working capital, tangible and intangible assets, goodwill, rights-of-use assets, investments in associates & joint ventures and other investments, and is taken as the average of the situation at the end of the last 4 quarters.
- (8) FCF Conversion is calculated as the ratio between the free cash flow to Solvay shareholders (before netting of dividends paid to non-controlling interest) and underlying EBITDA.